

The ISGIDAR NEWSLETTER

VOL. 28, NO. 2

May, 2003

<i>President of ISGIDAR</i>	<i>Secretary of ISGIDAR</i>
John R. Glowa, Ph.D. Pfizer Global Res & Devel CNS Discovery Groton Laboratories Eastern Point Rd MS8220-4188 Groton, CT 06340 tel: (860) 686-1835 email: john_glowa@groton.pfizer.com	Michael A. Nader, Ph.D. Department of Physiology & Pharmacology Wake Forest University School of Medicine Medical Center Blvd. Winston-Salem, NC, 27157 tel: (336) 713-7172 email: mnader@wfubmc.edu
<i>Chief Technology Officer</i>	<i>Treasurer of ISGIDAR</i>
Jonathan B. Kamien, Ph.D. BioPsych Consulting 3450 Vista Haven Road Sherman Oaks, CA 91403 email: jkamien@biopsych.com	Marilyn E. Carroll, Ph.D. Dept. of Psychiatry University of Minnesot Box 392 UMHC Minneapolis, MN 554544 (612) 626-6289 email: mcarroll@staff.tc.umn.edu

ISGIDAR e-mail address: ISGIDAR-L@venus.vcu.edu

INDEX

[2003 ISGIDAR SCIENTIFIC MEETING - Bal; Harbour, FL](#)

[NOMINATIONS FOR NEW MEMBERS](#)

[NOMINATIONS FOR OFFICERS](#)

[PRELIMINARY PROGRAM for 2003 SCIENTIFIC MEETING](#)

[RECENT PUBLICATIONS: ISGIDAR MEMBER BIBLIOGRAPHIES](#)

[POSITIONS AVAILABLE](#)

2003 ISGIDAR SCIENTIFIC MEETING – Bal Harbour, FL

The 2003 annual ISGIDAR Scientific Meeting will be held at the Sheraton Bal Harbour Beach Resort in Miami Beach, Florida immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence. ISGIDAR registration will begin at 8:00AM on Saturday, June 14, 2003. The registration fee is \$50. Paper presentations will be scheduled between 9:00AM and 5:00PM and the business meeting will be held from 5:00 to 5:30 PM.

If you wish to **advance register** (\$50 – does not include lunch), please send a check, payable to ISGIDAR, to Dr. Marilyn Carroll, Psychiatry Department, Box 392 UMHC, University of Minnesota, Minneapolis, MN 55455. Receipts for meal costs and registration will be provided at the meeting.

President Glowa has arranged lunch at a cost of \$28 per person. We have the capacity to seat 48 people at lunch and that number is fast approaching. If you intend to eat lunch at the meeting, please respond to Jace Glowa ASAP (john_glowa@groton.pfizer.com).

Nominations for New Members

Nominations for new members should be e-mailed to the [President of ISGIDAR](#) and will be collated for a vote by ballot preceding the next annual meeting.

Nominations for Officers

According to the By-Laws, the terms of the President and Secretary are two years. The Secretary has traditionally taken the Office of President at such junctures, and we will need to nominate a new Secretary this year. Nominations for Secretary can be e-mailed to the [President of ISGIDAR](#) or made on the floor of the business meeting, and will be voted on during that meeting. We also perpetually seek someone to relieve our Treasurer's annual burden, while we thank her for her patience and performance.

Preliminary Program

ISGIDAR PROGRAM

Bal Harbour, Florida

June 14, 2003

8:00 **Registration, coffee**

8:30 **Opening comments:**Jace Glowa, President

8:40 **Opioids, cocaine, and food change runtime distribution in a rat runway procedure.**Gerald Zernig, University of Innsbruck, Austria

9:00 **Using growth-curve modeling to describe and analyze the acquisition of drug self-administration in laboratory animals.** Eric Donny, Johns Hopkins University.

9:20 **Student Travel Award Winner- Subjective and reinforcing effects of smoking during negative affect.** Cynthia Conklin, University of Pittsburgh.

9:40 **The reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans. A dose-response analysis.** William Stoops, University of Kentucky.

10:00 **Coffee Break**

10:30 **Symposium: Agonist pharmacotherapy: Pro and Con**, Introduction by Michael Nader

- **Effects of substitute agonists for stimulant abuse in nonhuman primate models.** Leonard Howell, Emory University
- **High-affinity, slow-onset, long duration DAT-selective reuptake inhibitors as potential pharmacotherapies for cocaine addiction: Ideal?** Joshua Lile, University of Kentucky
- **Some thoughts on the evaluation of agonist medications for the treatment of cocaine dependence.** Steve Negus, Harvard University

12:00 **Lunch**

1:30 **Cocaine addiction: lessons learned.** Kathleen M. Kantak, Boston University.

1:50 **Recent findings on the reinforcing effects of cannabinoids.** Steve Goldberg, NIDA Intramural Research

2:10 **New evidence for opioid-cannabinoid interactions in drug-discrimination and drug self-administration models.** Marcello Solinas, NIDA Intramural Research

2:30 The behavioral significance of nicotine's differential ability to desensitize brain area nAChR's as evaluated in both a drug discrimination and cellular receptor model. Randy Jones, Virginia Commonwealth University.

2:50 Coffee Break

3:10 Price-based remifentanil choice in rhesus monkeys. Gail Winger, University of Michigan

3:30 Effects of response-contingent and non-contingent intravenous fentanyl on quantitative EEG activity in opioid-dependent volunteers. Mark Greenwald, Wayne State University

3:50 Intravenous self-administration of the endocannabinoid anandamide by squirrel monkeys and effects of CB1-receptor blockade and inhibition of anandamide transport. Zuzana Justinova, NIDA Intramural Research

4:15 Business Meeting

4:30 Refreshments

Recent Publications: ISGIDAR Member Bibliographies

William L. Woolverton, Ph.D.

- Ranaldi, R. and Woolverton, W.L. Self-administration of cocaine:scopolamine combinations by rhesus monkeys. *Psychopharmacology* 161: 442-448, 2002.
- Anderson, K.G., Velkey, A.J. and Woolverton, W.L.: The generalized matching law as a predictor of choice between cocaine and food in rhesus monkeys. *Psychopharmacology* 163: 319-326, 2002.
- Woolverton, W.L. and Ranaldi, R.: Comparison of the reinforcing efficacy of two dopamine D2-like receptor agonists in rhesus monkeys using a progressive-ratio schedule of reinforcement. *Pharmacol. Biochem. Behav.* 72: 803-809, 2002.
- Woolverton, W.L., Ranaldi, R., Wang, Z., Ordway, G.A., Paul, I.A., Petukhov, P. and Kozikowski, A.: Reinforcing strength of a novel dopamine transporter ligand: Pharmacodynamic and pharmacokinetic mechanisms., *J. Pharmacol. Exp. Ther.* 303: 211-217, 2002.

- Lile, J.A. Morgan, D., Birmingham, A.M., Wang, Z., Woolverton, W.L., Davies, H.M.L. and Nader, M.A.: The reinforcing efficacy of the dopamine reuptake inhibitor PTT as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. *J. Pharmacol. Exp. Ther.* 303: 640-648, 2002.
- McMahan, L.R., France, C.P., Winger, G. and Woolverton, W.L.: Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. *Eur. J. Pharmacol.*, in press.
- Anderson, K.A. and Woolverton, W.L.: Effects of dose and infusion delay on cocaine self-administration choice in rhesus monkeys. *Psychopharmacology*, in press

S. Stevens Negus, Ph.D.

- Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. *Neuropsychopharmacology* 28:919-931
- Negus SS, Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. *Drug Alcohol Depend* 70:39-52.
- Negus SS, Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. *Psychopharmacology*, in press.

POSITIONS AVAILABLE

Research Associate or Senior Research Associate, Department of Psychiatry, University of Mississippi Medical Center. Develop, implement and publish research relating to the neurobiological and behavioral effects of abused drugs, particularly in relation to drug self-administration by non-human primates. The relationship between brain monoamine transporters and drug reinforcement is a primary interest. A Ph.D. in Pharmacology, Neuroscience or Psychology is required. Salary will be commensurate with experience. Send c.v., description of research experience and goals, and names of three references to: William L. Woolverton, Ph.D., Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216. Or contact Dr. Woolverton at the CPDD meeting. EOE, M/F/D/V.

DRUG ABUSE TREATMENT PROGRAM, Applications are invited for a tenure-track position in the Department of Psychiatry and Human Behavior at the University of Mississippi Medical Center. The position will be at the assistant or associate professor level, depending upon qualifications. Candidates should have an M.D. and/or a Ph.D. in psychology, pharmacology or neuroscience with expertise in drug abuse treatment and treatment research. The successful candidate will be expected to develop an outpatient drug abuse treatment program with an externally funded research component and to establish collaborative relations with other scientists within the department. Salary will be commensurate with rank. Start-up funds and space are available. Applicants should send curriculum vitae, a statement of current and future research goals and names of three references to: Joseph Kwentus, M.D., Interim Chairman, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, EOE, M/F/D/V.

Postdoctoral Job description at McLean Hospital

Post-doctoral training positions are available in preclinical pharmacology and drug abuse research at McLean Hospital. Ongoing research is aimed at 1) comparative analysis of the reinforcing strength of self-administered drugs; 2) pharmacological studies of the behavioral effects of chronically administered GABAergic or dopaminergic ligands.

Applicants must be US citizens or permanent residents. Minorities are encouraged to apply. If interested, please send cover letter and c.v.

to: jbergman@hms.harvard.edu or to Jack Bergman / ADARC, McLean Hospital / 115Mill Street / Belmont MA 02478.